Mikko Lemola
Lexeo Therapeutics (LXEO), a developer of genetic medicines, has filed for an initial public offering.
Lexeo didn’t specify terms in its SEC filing, but indicated in an attached filing fee schedule that it was looking to raise $100M, a number that is likely a placeholder and subject to change.
The company hopes to list its shares on Nasdaq under the symbol LXEO. Bookrunners include JP Morgan, Leerink Partners, Stifel, RBC Capital Markets and Chardan.
Lexeo’s lead drug candidate, LX2006, is in Phase 1/2 testing for Friedrich’s Ataxia cardiomyopathy, with interim data expected in mid-2024. The company is also conducting Phase 1/2 testing on drug candidates for arrhythmogenic cardiomyopathy and Alzheimer’s disease.
